About NewAmsterdam Pharma
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.
Leadership at NewAmsterdam Pharma
The team at the top of the org chart.
Michael Davidson
CEO
72 reports
Matthew Philippe
Executive Vice President
18 reports
Douglas Kling
Chief Operating Officer
16 reports
David Topper
Chief Financial Officer
12 reports
BJ Jones
Chief Commercial Officer
10 reports
Michael Marino
Chief Legal Officer
4 reports
Marc Ditmarsch
Chief Development Officer
3 reports
John Kastelein
CSO
1 report
M. Ian Somaiya
Chief Financial Officer
Board
John Smither
Board Member
Stephen Nicholls
Clinical Advisory Board
Ann Marie Navar
Clinical Advisory Board
Christie Ballantyne
Clinical Advisory Board
Kosh Ray
Clinical Advisory Board
Brian Ference
Clinical Advisory Board
Open Jobs at NewAmsterdam Pharma (8)
- NewAmsterdam Pharma · Remote - USA · 3dFull-time
- NewAmsterdam Pharma · Remote - USA · 3dFull-time
- NewAmsterdam Pharma · Remote - USA · 3dFull-time
- NewAmsterdam Pharma · Remote - USA · 4dFull-time
- NewAmsterdam Pharma · Remote - USA · 4dFull-time
- NewAmsterdam Pharma · Remote - Pennsylvania · 4dFull-time
- NewAmsterdam Pharma · Remote - USA · 4dFull-time
- NewAmsterdam Pharma · Remote - USA · 4dFull-time